For VCs, angels, corporate venture and TTOs
Luxembourg deeptech, scored before it reaches you.
The M3TRL Deal Brief is a short quarterly selection of Luxembourg and Greater Region deeptech and life-science companies. Each one comes with an independent TRL/CRL scorecard, written by a PhD scientist and reviewed by a materials and engineering advisor for hardware companies, so you can decide in minutes whether to take the call.
What's in each issue
One page per company. The science checked.
Companies come from university and LIST spin-off pipelines, Fit 4 Start cohorts, incubators and direct applications. Only teams that pass a readiness review are included.
| Scorecard field | What it tells you |
|---|---|
| TRL (1–9) | How far the technology has been demonstrated, with the evidence seen |
| CRL (1–9) | Whether customers, regulators and supply chain are ready to adopt it |
| Regulatory path | Class, route (CE/MDR, EMA, FDA) and the next gate |
| Engineering risk | For hardware: manufacturability, scale-up and the physics behind the performance claims |
| IP position | Filed, granted or licensed; ownership with the university or company |
| Non-dilutive leverage | Grants secured or in progress (FNR, EIC, Fit 4 Start) |
| Round | Stage, ticket size sought, timing |
Deal sessions
45 minutes, online, three founders
Each quarter, subscribers can join a closed video session where three pre-vetted founders pitch for ten minutes each and take questions. No travel, no panels, no evening reception. Recordings are not shared.
- Choose your filterTell us your sectors, stages and ticket sizes once. You only get invited to sessions that match.
- Read the scorecardsSent a week before, with a short data-room index for each company.
- Meet directlyFollow-up meetings are between you and the founders. M3TRL does not take part in the investment decision.
Scientific & technical due diligence
An independent PhD-level read on a target's science and engineering
For funds without an in-house specialist. One provider covers biotech, medtech and diagnostics as well as materials, microfluidics, thermal and other hardware. A written report you can file with your investment memo.
- Science and claims check against the literature
- TRL/CRL assessment with evidence
- Top risks, in 5 working days
Hardware and materials targets from €4,000.
- Everything in the red-flag review
- Prior-art and freedom-to-operate overview (non-legal)
- Regulatory pathway, timeline and cost estimate
- For hardware: manufacturability and scale-up review
- Interview with the technical founders
Hardware and materials targets from €9,000.
- Quarterly TRL/CRL tracking of portfolio companies
- Grant and regulatory support for your founders
- Priced per number of companies
Prices exclude VAT. Due diligence is paid by the investor only, so the review stays independent. Any prior or current relationship with a company, including any connection of M3TRL's advisor, is disclosed before work starts. M3TRL does not review companies in fields where its advisor has a current employment conflict.
For founders
Want to be in the Deal Brief?
Inclusion is free and decided on readiness alone. Teams that are not yet ready get the gaps in writing and can work on them through the TRL Clinic or an Investor Readiness package.
- Deeptech, healthtech, biotech, materials, space or AI with a hardware or science core
- Operating in Luxembourg or the Greater Region, or relocating here
- Prototype at TRL 4 or higher
- Raising pre-seed to Series A in the next 12 months
- Apply through the form below and choose "Founder: apply for Deal Brief"
Subscribe
Get the next issue
For professional investors. Your details are used only to send the Deal Brief and session invitations, and you can unsubscribe at any time.
The Deal Brief is information about companies, not investment advice or an offer of securities. M3TRL does not handle investor funds, arrange transactions, or receive commissions on investments.